After shepherding Forma Therapeutics from its discovery stage to clinical trials as its R&D chief, John Hohneker is joining Anokion Therapeutics as president and CEO, effective Jan. 22.
“John brings tremendous experience in biologics development to Anokion, including in the immunology space. His broad leadership in both preclinical and clinical development will strengthen Anokion’s powerful platforms in immunological tolerance,” said Jeffrey Hubbell, the academic founder, chairman and chief scientific officer of Anokion, in a statement.
Anokion, a spinout of the Ecole Polytechnique Fédérale de Lausanne in Switzerland, is working on an antigen-specific immune tolerance platform for the development of new treatments for autoimmune disease.
The tech is designed for “diverse applications,” the company says, including tolerizing the immune system to self-antigens behind autoimmune diseases, as well as cutting the immunogenicity of therapeutic proteins.
The biotech is advancing two approaches to exploit the body’s natural tolerance mechanism of apoptotic, or aging, cells. Both involve engineering antigens to provoke a tolerogenic immune response—in the first, the antigens bind to a surface protein unique to red blood cells, while in the second, they bind to liver cells.
In addition to his R&D experience at Forma, Hohneker served in a number of roles at Novartis, most recently as senior vice president and global head of development for immunology and dermatology.
In January last year, Celgene plunked down $45 million up front to join forces with Anokion on tolerance-inducing treatments. Anokion stands to collect another $10 million if it hits certain preclinical performance marks, while Celgene picked up an equity interest in Anokion and the exclusive right to acquire the biotech at a later date.
By Amirah Al Idrus
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.